Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

Quadrosilan

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
Quadrosilan
Clinical data
Trade namesCisobitan
Other namesQuadrosilane; KABI-1774; 2,6-cisdiphenylhexa-
methylcyclotetrasiloxane
Drug classNonsteroidal estrogen
Identifiers
  • 2,2,4,6,6,8-hexamethyl-4,8-diphenyl-1,3,5,7,2,4,6,8-tetraoxatetrasilocane
CAS Number
PubChemCID
ChemSpider
UNII
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC18H28O4Si4
Molar mass420.758 g·mol−1
3D model (JSmol)
  • C[Si]1(O[Si](O[Si](O[Si](O1)(C)C2=CC=CC=C2)(C)C)(C)C3=CC=CC=C3)C
  • InChI=1S/C18H28O4Si4/c1-23(2)19-25(5,17-13-9-7-10-14-17)21-24(3,4)22-26(6,20-23)18-15-11-8-12-16-18/h7-16H,1-6H3
  • Key:ZTQZMPQJXABFNC-UHFFFAOYSA-N

Quadrosilan (INNTooltip International Nonproprietary Name,BANTooltip British Approved Name) (brand nameCisobitan; former developmental code nameKABI-1774) is asyntheticnonsteroidal estrogen that was developed in the 1970s and that is or has been used as anantigonadotropic agent in the treatment ofprostate cancer.[1][2][3][4] It is anorganosilicon compound, and is also known as2,6-cisdiphenylhexamethylcyclotetrasiloxane.[3][5] Quadrosilan hasestrogenic activity equivalent to that ofestradiol,[6] and can producefeminization andgynecomastia asside effects in male patients.[7][8]

See also

[edit]

References

[edit]
  1. ^Elks J (14 November 2014).The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 629–.ISBN 978-1-4757-2085-3.
  2. ^Morton IK, Hall JM (6 December 2012).Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 243–.ISBN 978-94-011-4439-1.
  3. ^abAlfthan O, Andersson L, Esposti PL, Fosså SD, Gammelgaard PA, Gjöres JE, et al. (1983). "Cisobitan in treatment of prostatic cancer. A prospective controlled multicentre study".Scandinavian Journal of Urology and Nephrology.17 (1):37–43.doi:10.3109/00365598309179778.PMID 6346476.
  4. ^Chisholm GD (1985). "Treatment of advanced cancer of the prostate".Seminars in Surgical Oncology.1 (1):38–55.doi:10.1002/ssu.2980010106.PMID 3887539.
  5. ^Apeloig Y (1989).The Chemistry of Organic Silicon Compounds. John Wiley & Sons Canada, Limited. p. 1154.ISBN 978-0-471-91993-3.
  6. ^Mills JS, Showell GA (September 2004). "Exploitation of silicon medicinal chemistry in drug discovery".Expert Opinion on Investigational Drugs.13 (9):1149–1157.doi:10.1517/13543784.13.9.1149.PMID 15330746.S2CID 26669175.
  7. ^Strindberg B (1978). "Biochemical Effects of 2, 6-cis-Diphenylhexamethylcyclotetrasiloxane in Man".Biochemistry of Silicon and Related Problems. pp. 515–520.doi:10.1007/978-1-4613-4018-8_23.ISBN 978-1-4613-4020-1.
  8. ^Krarup T, Rasmussen F, Gammelgaard PA (1978). "Prostatic carcinoma treated with 2,6-cis-diphenylhexamethylcyclotetrasiloxane (Cisobitan)".Scandinavian Journal of Urology and Nephrology.12 (1):11–15.PMID 345431.
Estrogens
ERTooltip Estrogen receptor agonists
Progonadotropins
Antiestrogens
ERTooltip Estrogen receptor antagonists
(incl.SERMsTooltip selective estrogen receptor modulators/SERDsTooltip selective estrogen receptor downregulators)
Aromatase inhibitors
Antigonadotropins
Others
GnRHTooltip Gonadotropin-releasing hormone andgonadotropins
GnRH modulators
(incl.analogues)
Agonists
Antagonists
Gonadotropins
Preparations
Others
(indirect)
Progonadotropins
Antigonadotropins
ERTooltip Estrogen receptor
Agonists
Mixed
(SERMsTooltip Selective estrogen receptor modulators)
Antagonists
GPERTooltip G protein-coupled estrogen receptor
Agonists
Antagonists
Unknown
Retrieved from "https://en.wikipedia.org/w/index.php?title=Quadrosilan&oldid=1161900568"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2025 Movatter.jp